Literature DB >> 6332147

The kinetics of [3H]-dsDNA/anti-DNA immune complex formation, binding by red blood cells, and release into serum: effect of DNA molecular weight and conditions of antibody excess.

C Horgan, J Burge, L Crawford, R P Taylor.   

Abstract

[3H]dsDNA/anti-DNA immune complexes (IC) formed, fixed complement, and bound rapidly to red blood cells (RBC) in whole blood (less than 5 min), but were released from the cells more slowly. The rate of release was dependent on both the antibody:DNA ratio and the m.w. of the DNA in the complex. For example, complexes formed with high m.w. DNA (6 X 10(6) daltons) were released more slowly (t1/2 = 60 min) than complexes formed with lower m.w. DNA (2 to 6 X 10(5) daltons, t1/2 = 15 to 20 min). The [3H]dsDNA/anti-DNA complexes, which were released from the cells as intact antigen/antibody/complement complexes, did not rebind to RBC, but did bind to Raji cells and could be precipitated by monoclonal antibody to C3d. When these released IC (RIC) containing high m.w. DNA were incubated with additional anti-DNA antibody and fresh complement, they rebound to RBC. However, RIC containing lower m.w. DNA (5 X 10(5) daltons) did not rebind to RBC under the same conditions. These data suggest that IC containing high m.w. DNA bind to and remain bound to RBC more effectively than IC containing lower m.w. DNA, and thus may be more easily cleared from the circulation by the RBC IC clearance mechanism. Thus, the size of the DNA in the IC may be a significant factor in the pathogenicity of DNA/anti-DNA complexes in SLE.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332147

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment.

Authors:  R P Taylor; W M Sutherland; C J Reist; D J Webb; E L Wright; R H Labuguen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

2.  Immune complexes and erythrocyte CR1 (complement receptor type 1): effect of CR1 numbers on binding and release reactions.

Authors:  Y C Ng; J A Schifferli; M J Walport
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

Review 3.  The aetiology and pathogenesis of major systemic vasculitides.

Authors:  C O Savage; Y C Ng
Journal:  Postgrad Med J       Date:  1986-07       Impact factor: 2.401

Review 4.  Complement activation and complement receptors in systemic lupus erythematosus.

Authors:  J P Atkinson
Journal:  Springer Semin Immunopathol       Date:  1986

5.  Tetanus toxoid-anti-tetanus toxoid complexes: a potential model to study the complement transport system for immune complex in humans.

Authors:  J P Paccaud; G Steiger; A G Sjöholm; P J Spaeth; J A Schifferli
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

6.  Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus.

Authors:  Jason S Knight; Wenpu Zhao; Wei Luo; Venkataraman Subramanian; Alexander A O'Dell; Srilakshmi Yalavarthi; Jeffrey B Hodgin; Daniel T Eitzman; Paul R Thompson; Mariana J Kaplan
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

7.  In vivo handling of soluble complement fixing Ab/dsDNA immune complexes in chimpanzees.

Authors:  R P Kimberly; J C Edberg; L T Merriam; S B Clarkson; J C Unkeless; R P Taylor
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

Review 8.  Clearance of cryoglobulins in man.

Authors:  Y C Ng; J A Schifferli
Journal:  Springer Semin Immunopathol       Date:  1988

9.  Blockade of clearance of immune complexes by an anti-Fc gamma receptor monoclonal antibody.

Authors:  S B Clarkson; R P Kimberly; J E Valinsky; M D Witmer; J B Bussel; R L Nachman; J C Unkeless
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.